Auto - Parts
Compare Stocks
5 / 10Stock Comparison
CREVW vs CREV vs THRM vs MPAA vs DORM
Revenue, margins, valuation, and 5-year total return — side by side.
Auto - Parts
Auto - Parts
Auto - Parts
Auto - Parts
CREVW vs CREV vs THRM vs MPAA vs DORM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Auto - Parts | Auto - Parts | Auto - Parts | Auto - Parts | Auto - Parts |
| Market Cap | — | $775K | $944M | $220M | $3.72B |
| Revenue (TTM) | $71M | $58M | $1.53B | $771M | $2.15B |
| Net Income (TTM) | $-221M | $-46M | $23M | $2M | $190M |
| Gross Margin | -155.1% | -40.2% | 23.6% | 19.2% | 40.7% |
| Operating Margin | -235.9% | -63.3% | 4.7% | 6.1% | 15.6% |
| Forward P/E | — | — | 11.8x | 15.5x | 15.0x |
| Total Debt | $111M | $111M | $295M | $201M | $633M |
| Cash & Equiv. | $4M | $4M | $161M | $9M | $49M |
CREVW vs CREV vs THRM vs MPAA vs DORM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 23 | Apr 26 | Return |
|---|---|---|---|
| Carbon Revolution P… (CREVW) | 100 | 6.3 | -93.8% |
| Carbon Revolution P… (CREV) | 100 | 1.2 | -98.8% |
| Gentherm Incorporat… (THRM) | 100 | 77.7 | -22.3% |
| Motorcar Parts of A… (MPAA) | 100 | 136.7 | +36.7% |
| Dorman Products, In… (DORM) | 100 | 183.6 | +83.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CREVW vs CREV vs THRM vs MPAA vs DORM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CREVW has the current edge in this matchup, primarily because of its strength in growth and stability.
- 86.8% revenue growth vs THRM's 2.6%
- Beta 0.80 vs CREV's 1.92
CREV is the clearest fit if your priority is growth exposure.
- Rev growth 86.8%, EPS growth 100.0%, 3Y rev CAGR 26.9%
THRM ranks third and is worth considering specifically for value.
- Lower P/E (11.8x vs 15.0x)
MPAA is the clearest fit if your priority is momentum.
- +24.3% vs CREVW's -89.7%
DORM is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 2 yrs, beta 0.85
- 129.7% 10Y total return vs THRM's -14.9%
- Lower volatility, beta 0.85, Low D/E 42.9%, current ratio 3.09x
- Beta 0.85, current ratio 3.09x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 86.8% revenue growth vs THRM's 2.6% | |
| Value | Lower P/E (11.8x vs 15.0x) | |
| Quality / Margins | 8.8% margin vs CREVW's -309.4% | |
| Stability / Safety | Beta 0.80 vs CREV's 1.92 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +24.3% vs CREVW's -89.7% | |
| Efficiency (ROA) | 7.6% ROA vs CREVW's -198.1%, ROIC 13.9% vs -27.1% |
CREVW vs CREV vs THRM vs MPAA vs DORM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CREVW vs CREV vs THRM vs MPAA vs DORM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DORM leads in 3 of 6 categories
MPAA leads 1 • CREVW leads 0 • CREV leads 0 • THRM leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DORM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DORM is the larger business by revenue, generating $2.2B annually — 37.3x CREV's $58M. DORM is the more profitable business, keeping 8.8% of every revenue dollar as net income compared to CREVW's -3.1%. On growth, CREV holds the edge at +107.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $71M | $58M | $1.5B | $771M | $2.2B |
| EBITDAEarnings before interest/tax | — | -$25M | $127M | $49M | $377M |
| Net IncomeAfter-tax profit | — | -$46M | $23M | $2M | $190M |
| Free Cash FlowCash after capex | — | -$62M | $79M | $30M | $71M |
| Gross MarginGross profit ÷ Revenue | -155.1% | -40.2% | +23.6% | +19.2% | +40.7% |
| Operating MarginEBIT ÷ Revenue | -2.4% | -63.3% | +4.7% | +6.1% | +15.6% |
| Net MarginNet income ÷ Revenue | -3.1% | -79.6% | +1.5% | +0.3% | +8.8% |
| FCF MarginFCF ÷ Revenue | -142.6% | -107.6% | +5.1% | +3.9% | +3.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +107.9% | +11.3% | -9.9% | +4.2% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -156.9% | — | -18.2% | -23.5% |
Valuation Metrics
MPAA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 18.8x trailing earnings, DORM trades at a 63% valuation discount to THRM's 51.4x P/E. On an enterprise value basis, MPAA's 8.2x EV/EBITDA is more attractive than DORM's 10.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | — | $775,174 | $944M | $220M | $3.7B |
| Enterprise ValueMkt cap + debt − cash | — | $78M | $1.1B | $412M | $4.3B |
| Trailing P/EPrice ÷ TTM EPS | — | — | 51.35x | -11.59x | 18.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 11.84x | 15.55x | 15.00x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 1.25x |
| EV / EBITDAEnterprise value multiple | — | — | 8.21x | 8.19x | 10.41x |
| Price / SalesMarket cap ÷ Revenue | — | 0.02x | 0.63x | 0.29x | 1.75x |
| Price / BookPrice ÷ Book value/share | — | — | 1.32x | 0.88x | 2.59x |
| Price / FCFMarket cap ÷ FCF | — | — | 15.45x | 5.39x | 49.18x |
Profitability & Efficiency
DORM leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
DORM delivers a 13.1% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $1 for MPAA. THRM carries lower financial leverage with a 0.41x debt-to-equity ratio, signaling a more conservative balance sheet compared to MPAA's 0.78x. On the Piotroski fundamental quality scale (0–9), MPAA scores 7/9 vs CREV's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | — | +3.2% | +0.8% | +13.1% |
| ROA (TTM)Return on assets | -198.1% | -25.2% | +1.6% | +0.2% | +7.6% |
| ROICReturn on invested capital | -27.1% | -27.1% | +7.3% | +6.2% | +13.9% |
| ROCEReturn on capital employed | -3.1% | -3.1% | +8.2% | +6.6% | +18.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 5 | 7 | 7 |
| Debt / EquityFinancial leverage | — | — | 0.41x | 0.78x | 0.43x |
| Net DebtTotal debt minus cash | $107M | $107M | $134M | $192M | $584M |
| Cash & Equiv.Liquid assets | $4M | $4M | $161M | $9M | $49M |
| Total DebtShort + long-term debt | $111M | $111M | $295M | $201M | $633M |
| Interest CoverageEBIT ÷ Interest expense | -6.46x | -6.46x | 5.83x | 0.94x | 8.24x |
Total Returns (Dividends Reinvested)
Evenly matched — MPAA and DORM each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DORM five years ago would be worth $11,922 today (with dividends reinvested), compared to $137 for CREV. Over the past 12 months, MPAA leads with a +24.3% total return vs CREVW's -89.7%. The 3-year compound annual growth rate (CAGR) favors MPAA at 34.5% vs CREV's -76.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -51.4% | -76.8% | -16.3% | -7.2% | +0.3% |
| 1-Year ReturnPast 12 months | -89.7% | -85.9% | +19.1% | +24.3% | +0.5% |
| 3-Year ReturnCumulative with dividends | — | -98.6% | -48.0% | +143.5% | +41.6% |
| 5-Year ReturnCumulative with dividends | — | -98.6% | -58.0% | -51.7% | +19.2% |
| 10-Year ReturnCumulative with dividends | — | -98.6% | -14.9% | -62.7% | +129.7% |
| CAGR (3Y)Annualised 3-year return | — | -76.1% | -19.6% | +34.5% | +12.3% |
Risk & Volatility
Evenly matched — CREVW and THRM each lead in 1 of 2 comparable metrics.
Risk & Volatility
CREVW is the less volatile stock with a 0.80 beta — it tends to amplify market swings less than CREV's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. THRM currently trades 78.0% from its 52-week high vs CREV's 4.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.61x | 1.69x | 1.44x | 0.93x | 0.95x |
| 52-Week HighHighest price in past year | $0.05 | $9.20 | $39.48 | $18.12 | $166.89 |
| 52-Week LowLowest price in past year | $0.00 | $0.01 | $25.47 | $9.09 | $98.44 |
| % of 52W HighCurrent price vs 52-week peak | +6.8% | +4.4% | +78.0% | +63.3% | +74.6% |
| RSI (14)Momentum oscillator 0–100 | 34.2 | 44.2 | 59.7 | 58.0 | 71.2 |
| Avg Volume (50D)Average daily shares traded | 61K | 188K | 239K | 87K | 273K |
Analyst Outlook
DORM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: THRM as "Buy", MPAA as "Buy", DORM as "Buy". Consensus price targets imply 74.4% upside for MPAA (target: $20) vs 12.4% for DORM (target: $140).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $36.67 | $20.00 | $140.00 |
| # AnalystsCovering analysts | — | — | 15 | 7 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 0 | — | 2 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | — | 0.0% | +1.1% | +2.2% | +1.1% |
DORM leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MPAA leads in 1 (Valuation Metrics). 2 tied.
CREVW vs CREV vs THRM vs MPAA vs DORM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CREVW or CREV or THRM or MPAA or DORM a better buy right now?
For growth investors, Carbon Revolution Public Limited Company Warrant (CREVW) is the stronger pick with 86.
8% revenue growth year-over-year, versus 2. 6% for Gentherm Incorporated (THRM). Dorman Products, Inc. (DORM) offers the better valuation at 18. 8x trailing P/E (15. 0x forward), making it the more compelling value choice. Analysts rate Gentherm Incorporated (THRM) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CREVW or CREV or THRM or MPAA or DORM?
On trailing P/E, Dorman Products, Inc.
(DORM) is the cheapest at 18. 8x versus Gentherm Incorporated at 51. 4x. On forward P/E, Gentherm Incorporated is actually cheaper at 11. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CREVW or CREV or THRM or MPAA or DORM?
Over the past 5 years, Dorman Products, Inc.
(DORM) delivered a total return of +19. 2%, compared to -98. 6% for Carbon Revolution Public Limited Ordinary Shares (CREV). Over 10 years, the gap is even starker: DORM returned +129. 0% versus CREV's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CREVW or CREV or THRM or MPAA or DORM?
By beta (market sensitivity over 5 years), Carbon Revolution Public Limited Company Warrant (CREVW) is the lower-risk stock at 0.
61β versus Carbon Revolution Public Limited Ordinary Shares's 1. 69β — meaning CREV is approximately 176% more volatile than CREVW relative to the S&P 500. On balance sheet safety, Gentherm Incorporated (THRM) carries a lower debt/equity ratio of 41% versus 78% for Motorcar Parts of America, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CREVW or CREV or THRM or MPAA or DORM?
By revenue growth (latest reported year), Carbon Revolution Public Limited Company Warrant (CREVW) is pulling ahead at 86.
8% versus 2. 6% for Gentherm Incorporated (THRM). On earnings-per-share growth, the picture is similar: Carbon Revolution Public Limited Ordinary Shares grew EPS 100. 0% year-over-year, compared to -70. 9% for Gentherm Incorporated. Over a 3-year CAGR, CREVW leads at 26. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CREVW or CREV or THRM or MPAA or DORM?
Dorman Products, Inc.
(DORM) is the more profitable company, earning 9. 6% net margin versus -309. 4% for Carbon Revolution Public Limited Ordinary Shares — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DORM leads at 16. 8% versus -235. 9% for CREV. At the gross margin level — before operating expenses — DORM leads at 41. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CREVW or CREV or THRM or MPAA or DORM more undervalued right now?
On forward earnings alone, Gentherm Incorporated (THRM) trades at 11.
8x forward P/E versus 15. 5x for Motorcar Parts of America, Inc. — 3. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MPAA: 74. 4% to $20. 00.
08Which pays a better dividend — CREVW or CREV or THRM or MPAA or DORM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CREVW or CREV or THRM or MPAA or DORM better for a retirement portfolio?
For long-horizon retirement investors, Carbon Revolution Public Limited Company Warrant (CREVW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
61)). Carbon Revolution Public Limited Ordinary Shares (CREV) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CREVW and CREV and THRM and MPAA and DORM?
Both stocks operate in the Consumer Cyclical sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CREVW is a small-cap high-growth stock; CREV is a small-cap high-growth stock; THRM is a small-cap quality compounder stock; MPAA is a small-cap quality compounder stock; DORM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.